Who is sponsoring NCT01378117?

NCT01378117 is sponsored by Emory University.

What condition does NCT01378117 study?

NCT01378117 studies Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia.

What drugs are being tested in NCT01378117?

Interventions: Sitagliptin, glargine, lispro.

What is the status of NCT01378117?

NCT01378117 is currently COMPLETED.

Last reviewed 2018-11-05 · How we verify

Randomized Controlled Study of Dipeptidyl Peptidase-4 (DPP4) Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes

NCT01378117 Phase 4 COMPLETED Results posted

The study is a multicenter, prospective, open-label, randomized pilot study to investigate the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.

Details

Lead sponsor	Emory University
Phase	Phase 4
Status	COMPLETED
Enrolment	90
Start date	2011-08
Completion	2012-06

Conditions

Type 2 Diabetes Mellitus
Hospitalization
Hyperglycemia

Interventions

Sitagliptin
glargine
lispro

Primary outcomes

Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy — Admission and after 1st day of therapy
The primary outcome of the study is to determine differences in glycemic control as measured by mean BG concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with type 2 diabetes mellitus, at the time of admission to the blood glucose levels 24hrs after the therapy

Countries

United States